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The HSV-1 VP22 protein forms part of the viral tegument, a poorly understood region of the virion located between the capsid and the envelope. 2 The recent discovery that VP22 possesses novel trafficking properties in both transfected and virally infected cells 3 has aroused significant interest in its potential as a protein delivery vehicle. In infected cells, cytoplasmically located VP22 is rapidly excreted via a Golgi-independent pathway and is subsequently imported into neighbouring uninfected cells by a process requiring an intact actin cytoskeleton. Imported VP22 accumulates in the nucleus, where it may affect the regulation of cellular factors, increasing susceptibility to HSV infection 3 . The inter-cellular spread of VP22 appears to be a highly efficient process, with VP22 synthesised in one microinjected cell capable of reaching up to 200 surrounding cells. 3 Although the precise role of VP22 trafficking in the virus life cycle has not been determined, exploiting its unique properties is clearly an attractive gene therapy strategy. The ability of VP22 to retain its trafficking function as a fusion protein genetically linked to a peptide tag or marker protein (GFP) initially demonstrated that VP22 could be used for inter-cellular delivery of heterologous proteins. 3 Furthermore, VP22-directed delivery could be achieved either by transfection or by exogenous application of a protein extract. 3 In spite of these promising results from the O'Hare group, a controversial report in the October issue of Gene Therapy declared that intercellular trafficking of a VP22-GFP fusion protein was not observed in cultured mammalian cells. 4 A brief communication 5 in this issue, however, presents evidence that experimental conditions are critical to demonstrate the spread of VP22 fusion proteins.
The O'Hare laboratory have now confirmed and extended their earlier results, and in this issue, Dilber et al. present their successful combination of the novel VP22 technology with that of the well studied and highly promising enzyme/prodrug, or "suicide" gene therapy strategy for the treatment of cancer. 1 The most commonly used suicide gene therapy strategy involves delivery of HSV-1 thymidine kinase (TK) to cancer cells, and subsequent administration of the anti-herpes drug ganciclovir (GCV). HSV TK phosphorylates GCV, yielding a toxic metabolite which acts as a DNA polymerase inhibitor and chain terminator, thus leading exclusively to the death of prodrug-treated, TK-expressing cells. The success of the TK/GCV system in cancer gene therapy, has, however, been limited to those cancers in which a 'bystander effect' can be observed, whereby cytotoxicity is observed in cells not transduced with the effector gene. Recent work has clearly demonstrated that gap junctions are important mediators of the bystander effect both in vitro and in vivo. 6 In a significant fraction of malignant tumours, most notably glioblastomas, poor expression of the major gap junction protein, connexin, severely restricts the bystander effect, and hence the success of the TK/GCV strategy. 6 Significantly, Dilber et al. demonstrate that in VP22-TK expressing cells devoid of gap junction activity, the addition of GCV resulted in a cytotoxic bystander effect in vitro, and cytotoxicity leading to tumour regression in vivo. 1 The VP22 system may therefore be a powerful tool to bypass the dependence of suicide gene therapy on gap junction activity.
While its use in suicide gene therapies for cancer is perhaps its most exciting future, the unique ability of the VP22 system to turn a previous limitation of gene therapy, that of restricted delivery, to its advantage, make it an attractive delivery vehicle for numerous gene therapy strategies. Non-suicide cancer gene therapy should also benefit from this novel approach; indeed the widespread delivery of functional p53 protein to a human tumour cell line, and the resulting induction of apoptosis, has already been achieved. 7 Even the extensive innate immune response to adenovirus vectors may be overcome by delivering a low dose of adenovirus-VP22-transgene, such that the immune response is minimised yet sufficient transgene is delivered to elicit a therapeutic response. The VP22 strategy may also be of particular benefit in non-viral delivery systems. Direct injection of DNA is one of the cheapest, simplest and least immunogenic methods of transgene delivery, but has previously been an unattractive option due to its poor transduction efficiency. Direct injection of a VP22-transgene fusion, however, may achieve a far greater level of transduction, sufficient to make this a viable in vivo strategy. VP22-mediated delivery may also be of benefit in ex-vivo treatment and in the delivery of transgenes to cells which are particularly resistant to viral transduction.
Although the VP22 system is clearly an exciting addition to current gene therapy strategies, nuclear localisation of the imported fusion protein may limit its potential for treating disorders of cytoplasmic or plasma membrane origin. A further consideration must be the continuous supply of VP22 fusion protein from transduced cells, which may be limited by the immunogenicity of transgene products and of VP22 itself. The establishment of a stably transformed sub-population may overcome this by providing a constant source of the fusion protein. An additional concern stems from our current ignorance of the function of VP22 in the viral life cycle. The effects of the nuclear accumulation of VP22 on cellular function requires further investigation before VP22-mediated delivery could be tested in human trials. The use of truncated VP22 proteins may minimise any regulatory effects on cellular factors while retaining the domains essential for trafficking.
In summary, VP22-mediated delivery of transgene products may be a promising strategy for successful gene therapy, overcoming current problems associated with limited delivery. The incorporation of this novel approach into current targeting strategies offers great potential for the future development of efficacious gene therapies.
